BioSpace News Archive

Data from AMF’s American Registry for Migraine Research informed a study looking at headache days and disability.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced results from the company’s Phase 1 single ascending dose and multiple ascending dose clinical trial of VK0214, a novel, orally available small molecule thyroid receptor beta agonist in development for the potential treatment for X-linked adrenoleukodystrophy.

BeiGene, Ltd. announced that the first patient was dosed in the global Phase 3 AdvanTIG-302 trial of BeiGene’s investigational anti-TIGIT antibody ociperlimab in combination with its anti-PD-1 antibody tislelizumab, for the first-line treatment of patients with locally advanced, unresectable, or metastatic non-small cell lung cancer whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations.

Mevion Medical Systems announced the upgrade of the MEVION S250 Proton Therapy System at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO, to a MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning and FLASH capabilities.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that it will host a Key Opinion Leader call on July 15th, 2021 from 4 pm CET / 10 am ET to 5 pm CET / 11 am ET.

The British Skin Foundation describes a keloid scar as an overgrown scar that spreads beyond the original area of the damaged skin.

Rapid and accurate treatment and diagnosis of various clinical disorders are vital for best clinical outcome. Enzymes find extensive use in the diagnosis of an extensive range of illnesses, thanks to its excellent biocatalytic properties.

Assisted reproduction technology devices have been designed and developed to solve issues pertaining to fertility.

The global hemoconcentrators market is projected to exhibit a steady growth owing to the increasing demand for improved healthcare solutions for patients with cardiovascular diseases.

Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces that the ONCOS-102 and durvalumab trial in patients with advanced peritoneal malignancies has completed enrollment in the colorectal cancer cohort.